Pfizer’s Second-Quarter Results Top Street Views Boosted by COVID-19 Vaccine Sales; Raises Low End of Earnings Outlook

Pfizer recorded a 92% jump in second-quarter earnings that exceeded analysts’ expectations as the drugmaker recorded an “all-time” high in quarterly COVID-19 vaccine sales and lifted the lower end of its full-year profit outlook range. The company on Thursday posted adjusted earnings of $2.04 per share, advancing from $1.06 a Continue Reading